- Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
- Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
- Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
- Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
- Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
- Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
- Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
- Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
- Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
- Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
More ▼
Key statistics
As of last trade, Amarin Corporation PLC (AMRN:NMQ) traded at 1.29, 24.04% above the 52 week low of 1.04 set on Sep 23, 2022.
52-week range
Open | 1.27 |
---|---|
High | 1.30 |
Low | 1.26 |
Bid | 1.28 |
Offer | 1.29 |
Previous close | 1.26 |
Average volume | 1.92m |
---|---|
Shares outstanding | 387.41m |
Free float | 361.03m |
P/E (TTM) | -- |
Market cap | 488.13m USD |
EPS (TTM) | -0.2268 USD |
Data delayed at least 15 minutes, as of Jun 07 2023 16:50 BST.
More ▼